354 related articles for article (PubMed ID: 21695190)
1. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.
Hix LM; Shi YH; Brutkiewicz RR; Stein PL; Wang CR; Zhang M
PLoS One; 2011; 6(6):e20702. PubMed ID: 21695190
[TBL] [Abstract][Full Text] [Related]
2. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
Seki T; Liu J; Brutkiewicz RR; Tsuji M
Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
[TBL] [Abstract][Full Text] [Related]
3. Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.
Rao P; Wen X; Lo JH; Kim S; Li X; Chen S; Feng X; Akbari O; Yuan W
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185591
[TBL] [Abstract][Full Text] [Related]
4. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.
Webb TJ; Giuntoli RL; Rogers O; Schneck J; Oelke M
Clin Cancer Res; 2008 Dec; 14(23):7652-8. PubMed ID: 19047090
[TBL] [Abstract][Full Text] [Related]
5. CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.
Li Y; Zhao C; Liu J; Lu Z; Lu M; Gu J; Liu R
Oncol Rep; 2019 May; 41(5):2679-2688. PubMed ID: 30864713
[TBL] [Abstract][Full Text] [Related]
6. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
7. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
8. A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.
Wen X; Kim S; Xiong R; Li M; Lawrenczyk A; Huang X; Chen SY; Rao P; Besra GS; Dellabona P; Casorati G; Porcelli SA; Akbari O; Exley MA; Yuan W
J Immunol; 2015 Aug; 195(4):1459-69. PubMed ID: 26157173
[TBL] [Abstract][Full Text] [Related]
9. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.
Gebremeskel S; Lobert L; Tanner K; Walker B; Oliphant T; Clarke LE; Dellaire G; Johnston B
Cancer Immunol Res; 2017 Dec; 5(12):1086-1097. PubMed ID: 29054890
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Tiper IV; Webb TJ
Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
[TBL] [Abstract][Full Text] [Related]
12. CD252 regulates mast cell mediated, CD1d-restricted NKT-cell activation in mice.
Gonzalez Roldan N; Orinska Z; Ewers H; Bulfone-Paus S
Eur J Immunol; 2016 Feb; 46(2):432-9. PubMed ID: 26564814
[TBL] [Abstract][Full Text] [Related]
13. Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice.
VanderLaan PA; Reardon CA; Cabana VG; Wang CR; Getz GS
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540125
[TBL] [Abstract][Full Text] [Related]
14. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
Front Immunol; 2020; 11():610010. PubMed ID: 33312179
[TBL] [Abstract][Full Text] [Related]
15. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.
Weng X; He Y; Visvabharathy L; Liao CM; Tan X; Balakumar A; Wang CR
J Hepatol; 2017 Oct; 67(4):791-800. PubMed ID: 28596110
[TBL] [Abstract][Full Text] [Related]
17. Complementary approaches to study NKT cells in cancer.
Berzofsky JA; Olkhanud PB; Terabe M
Methods Enzymol; 2020; 631():371-389. PubMed ID: 31948558
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
Webb TJ; Bieler JG; Schneck JP; Oelke M
J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
[TBL] [Abstract][Full Text] [Related]
19. CD1d-dependent expansion of NKT follicular helper cells in vivo and in vitro is a product of cellular proliferation and differentiation.
Rampuria P; Lang ML
Int Immunol; 2015 May; 27(5):253-63. PubMed ID: 25710490
[TBL] [Abstract][Full Text] [Related]
20. All-trans-retinoic acid and CD38 ligation differentially regulate CD1d expression and α-galactosylceramide-induced immune responses.
Chen Q; Ross AC
Immunobiology; 2015 Jan; 220(1):32-41. PubMed ID: 25248321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
